181 related articles for article (PubMed ID: 28155012)
1. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.
Merryman RW; Armand P
Curr Hematol Malig Rep; 2017 Feb; 12(1):44-50. PubMed ID: 28155012
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint blockade in lymphoma.
Armand P
Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
[TBL] [Abstract][Full Text] [Related]
5. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
Chen YS; Shen CR
Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL; Drake CG; Pardoll DM
Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
11. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
16. Relation between costimulatory molecule polymorphism and hepatitis B infections in hematopoietic stem cell transplant recipients.
Yaghobi R; Saadi MI; Karimi MH; Geramizadeh B; Ramzi M; Zakerinia M
Exp Clin Transplant; 2014 Aug; 12(4):357-66. PubMed ID: 24188429
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.
Zhu J; Chen J
Mol Biol Rep; 2023 Mar; 50(3):2909-2917. PubMed ID: 36572760
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
